Source: http://www.google.com/patents/US7879212?dq=6,128,731
Timestamp: 2014-07-11 21:07:01
Document Index: 368945410

Matched Legal Cases: ['Application No. 04700494', 'Application No. 05747261', 'Application No. 03777149', 'Application No. 06796163', 'Application No. 05774727', 'Application No. 09002048', 'Application No. 03777149', 'Application No. 03777149', 'Application No. 04700494', 'Application No. 03777149', 'Application No. 04700494', 'Application No. 03777149', 'Application No. 04700494', 'Application No. 1510', 'Application No. 1499', 'Application No. 1400', 'Application No. 169120', 'Application No. 169120', 'Application No. 169121', 'Application No. 169120', 'Application No. 169120', 'Application No. 169121', 'Application No. 169121', 'Application No. 09002048', 'Application No. 03777149', 'Application No. 03777149', 'Application No. 05747261', 'Application No. 09002048', 'Application No. 03777149', 'Application No. 04700494', 'Application No. 04700494', 'Application No. 169121', 'Application No. 03704977', 'Application No. 05747261', 'Application No. 05747261']

Patent US7879212 - electrodes coated with self-assembled peptides containing nanostructures ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsAn electrode coated with peptide nanostructures, composed of self-assembled peptides, is disclosed. The electrode is capable of conducting a response current resulting from an electrochemical reaction. The electrode can form a part of an electrochemical cell, a detector and a sensor array. Methods utilizing...http://www.google.com/patents/US7879212?utm_source=gb-gplus-sharePatent US7879212 - electrodes coated with self-assembled peptides containing nanostructures exhibit enhanced electrochemical sensitivity and thus are highly suitable for use in electrochemical detection of various molecules and particularly as sensitive biosensors in biomolecular diagnosticsAdvanced Patent SearchPublication numberUS7879212 B2Publication typeGrantApplication numberUS 11/591,613Publication dateFeb 1, 2011Filing dateNov 2, 2006Priority dateNov 3, 2005Also published asUS20070138007Publication number11591613, 591613, US 7879212 B2, US 7879212B2, US-B2-7879212, US7879212 B2, US7879212B2InventorsMiri Yemini, Meital Reches, Judith Rishpon, Ehud GazitOriginal AssigneeRamot At Tel-Aviv University Ltd.Export CitationBiBTeX, EndNote, RefManPatent Citations (108), Non-Patent Citations (246), Classifications (4), Legal Events (2) External Links: USPTO, USPTO Assignment, Espacenetelectrodes coated with self-assembled peptides containing nanostructures exhibit enhanced electrochemical sensitivity and thus are highly suitable for use in electrochemical detection of various molecules and particularly as sensitive biosensors in biomolecular diagnosticsUS 7879212 B2Abstract An electrode coated with peptide nanostructures, composed of self-assembled peptides, is disclosed. The electrode is capable of conducting a response current resulting from an electrochemical reaction. The electrode can form a part of an electrochemical cell, a detector and a sensor array. Methods utilizing an electrochemical cell, a detector or a sensor array comprising the electrode for detecting an Analyte in a sample and kits containing same are also disclosed.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2920080Nov 24, 1958Jan 5, 1960Les Laboratoires Francais de ChimiotherapieProcess of preparing tryptamineUS3042685Apr 13, 1959Jul 3, 1962 Process of making g-fluoro tryptamineUS3625973Aug 1, 1968Dec 7, 1971Pasteur InstitutPreparation of oxygen containing indole derivativesUS3790596May 14, 1971Feb 5, 1974V AvramenkoMethod of producing indole and substitution products of the sameUS3853987Sep 1, 1971Dec 10, 1974W DreyerImmunological reagent and radioimmuno assayUS3867517Dec 21, 1971Feb 18, 1975Abbott LabDirect radioimmunoassay for antigens and their antibodiesUS3935074Dec 17, 1973Jan 27, 1976Syva CompanyAntibody steric hindrance immunoassay with two antibodiesUS3976639Mar 31, 1975Aug 24, 1976Hoffmann-La Roche Inc.Intermediates for indolesUS3984533Nov 13, 1975Oct 5, 1976General Electric CompanyElectrophoretic method of detecting antigen-antibody reactionUS4036945May 3, 1976Jul 19, 1977The Massachusetts General HospitalRadioactive antibodiesUS4299917Jan 21, 1980Nov 10, 1981Boehringer Manneheim GmbhImpregnation of an absorbent carrier with a sulphonphthalein ester and an activatorUS4331647Mar 3, 1980May 25, 1982Goldenberg Milton DavidTumor localization and therapy with labeled antibody fragments specific to tumor-associated markersUS4626540Oct 10, 1984Dec 2, 1986Warner-Lambert CompanySubstituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with themUS4666828Aug 15, 1984May 19, 1987The General Hospital CorporationTest for Huntington's diseaseUS4801531Sep 30, 1985Jan 31, 1989Biotechnology Research Partners, Ltd.Digestion with restriction enzyme, hybridizationUS4816567Apr 8, 1983Mar 28, 1989Genentech, Inc.Immunology, vectors, dnaUS4873316Jun 23, 1987Oct 10, 1989Biogen, Inc.Isolation of exogenous recombinant proteins from the milk of transgenic mammalsUS4925673Aug 14, 1987May 15, 1990Clinical Technologies Associates, Inc.Delivery systems for pharmacological agents encapsulated with proteinoidsUS4946778Jan 19, 1989Aug 7, 1990Genex CorporationSingle polypeptide chain binding moleculesUS4970233Aug 4, 1987Nov 13, 1990Mchugh John EAdministering phenolphthaleinUS5013556Oct 20, 1989May 7, 1991Liposome Technology, Inc.Lipids derivatized with polyoxyethylene glycol, drug delivery, antitumor agentsUS5270163Aug 17, 1992Dec 14, 1993University Research CorporationMethods for identifying nucleic acid ligandsUS5272057Oct 14, 1988Dec 21, 1993Georgetown UniversityMethod of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymeraseUS5304470Jan 23, 1992Apr 19, 1994Forschungszentrum Juelich GmbhProcess for the enzymatic preparation of protected and unprotected di- and oligopeptides in aqueous solutionsUS5332648Dec 27, 1991Jul 26, 1994Kabushiki Kaisha ToshibaAlklali soluble phenolic polymer, cyclic ester or sulfonate which converts to the acid, an onium salt which generates an an acid on exposure to radiationUS5475096Jun 10, 1991Dec 12, 1995University Research CorporationBinding to three-dimensional targetsUS5545806Dec 16, 1992Aug 13, 1996Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodiesUS5545807Aug 5, 1994Aug 13, 1996The Babraham InstituteProduction of antibodies from transgenic animalsUS5556744Mar 24, 1994Sep 17, 1996The Trustees Of The University Of PennsylvaniaMethods and compositions for diagnosing and treating certain HIV infected patientsUS5567588Jun 5, 1995Oct 22, 1996University Research CorporationForming nucleic acid-target complexes; partitioning increased affinity nucleic acids; amplificationUS5569825Dec 17, 1991Oct 29, 1996Genpharm InternationalTransgenic non-human animals capable of producing heterologous antibodies of various isotypesUS5595877May 16, 1995Jan 21, 1997Nexstar Pharmaceuticals, Inc.Methods of producing nucleic acid ligandsUS5625126Dec 7, 1994Apr 29, 1997Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodiesUS5633425Feb 5, 1992May 27, 1997Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodiesUS5637459Aug 2, 1994Jun 10, 1997Nexstar Pharmaceuticals, Inc.Systematic evolution of ligands by exponential enrichment: chimeric selexUS5643768Jun 6, 1995Jul 1, 1997Optein, Inc.Cell-free synthesis and isolation of novel genes and polypeptidesUS5658754Nov 29, 1991Aug 19, 1997Optein, Inc.Cell-free synthesis and isolation of novel genes and polypeptidesUS5659041Sep 2, 1994Aug 19, 1997Resolution Pharmaceuticals, Inc.Medical diagnosis, therapyUS5661016Apr 26, 1993Aug 26, 1997Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypesUS5683867Apr 28, 1994Nov 4, 1997Nexstar Pharmaceuticals, Inc.Nucleic acid ligands, blending, partitioning and amplificationUS5705337Mar 8, 1995Jan 6, 1998Nexstar Pharmaceuticals, Inc.Nucleic acid detection of ligands that bind covalently with target molecule complexesUS5916642Nov 21, 1996Jun 29, 1999Northwestern UniversityGenerating a vapor of the material to be encapsulated such as copper and germenium, generating hydrogen arc discharge that discharge encapsulating product, contacting vapor of material and discharge product to encapsulate material in carbon tubeUS5977302Nov 18, 1998Nov 2, 1999Ortho-Mcneil Pharmaceutical, Inc.Liquid phase process for the preparation of GnRH peptidesUS6110590Jun 12, 1998Aug 29, 2000The University Of AkronHexafluoroisopropanol, electrospinning, no acid treatmentUS6162828Mar 29, 1996Dec 19, 2000Takeda Chemical Industries, Ltd.Cysteine protease inhibitorUS6235876Jul 8, 1999May 22, 2001Ortho-Mcneil Pharmaceutical, Inc.Liquid phase process for the preparation of GNRH peptidesUS6251625Jun 26, 1996Jun 26, 2001Degussa AktiengesellschaftEnzymatic preparation of protected di- or oligopeptides and removal of the protective group used by splitting offUS6255286Jun 25, 1997Jul 3, 2001Nisshin Flour Milling Co., Ltd.Depsipeptides and drugs containing the same as the active ingredientUS6261569Aug 27, 1993Jul 17, 2001Deakin Research LimitedAntigens; mixed with carriers; genetic engineeringUS6300141 *Mar 2, 2000Oct 9, 2001Helix Biopharma CorporationCard-based biosensor deviceUS6303567Aug 27, 1996Oct 16, 2001Praecis Pharmaceuticals, Inc .Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS6309669Jan 27, 1997Oct 30, 2001The United States Of America As Represented By The Secretary Of The ArmyTherapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrixUS6326174Dec 1, 1995Dec 4, 2001The Scripps Research InstituteIsolating catalytic nucleic acids; obtain single stranded nucleotide sequences, mix with substrate, separate single-stranded nucleotide sequences, recover catalytic single stranded nucleotide sequencesUS6359112Jun 12, 1998Mar 19, 2002Fraunhofer-Gesellschaft Zur Forferung Der Angewandten Forschung E.V.Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathiesUS6361861Jun 14, 1999Mar 26, 2002Battelle Memorial InstituteCarbon nanotubes on a substrateUS6376233 *May 11, 1999Apr 23, 2002Micronas Intermetall GmbhDevice for conducting research on cell specimens and similar materialsUS6472436Jul 17, 2000Oct 29, 2002The Salk Institute For Biological StudiesBlocking amyloid protein toxicity in cells using polycylic compounds. also provided are novel methods of decreasing amyloid protein production in cells and methods of inhibiting cell death. invention methods can be used to prevent and treatUS6593339May 25, 2000Jul 15, 2003Astrazeneca AbUse of compounds as antibacterial agentsUS6610478Aug 15, 1997Aug 26, 2003Yale UniversityPhenotypic conversion of cells mediated by external guide sequencesUS6613875Oct 14, 1994Sep 2, 2003The Scripps Research InstituteHydrophobic amino acid residue for solubilizing to a lipid membrane; self-assembly by stacking upon one another with formation of hydrogen bonds; stable disk conformation; used as drug carriers, molecular sieves, reaction vesselsUS6617114Apr 30, 1998Sep 9, 2003Karo Bio AbIdentification of drug complementary combinatorial librariesUS6677153Nov 29, 2000Jan 13, 2004Avi Biopharma, Inc.Antisense antibacterial method and compositionUS6689753Nov 4, 2000Feb 10, 2004Axonyx, Inc.Alzheimer inhibitor peptide ia beta 5 (amino acid sequence 1leu-pro-phe-phe-asp) analogUS6762331Feb 13, 2002Jul 13, 2004Postech FoundationSynthesis of organic nanotubes and synthesis of ultrathin nanowires using same as templatesUS6858318Sep 17, 2001Feb 22, 2005Japan Science And Technology CorporationReducing a nanofiber comprising a metal complex peptide lipid formed from the two-headed peptide lipid and metal ion, using reducing agentUS6976639Dec 6, 2001Dec 20, 2005Edc Biosystems, Inc.Apparatus and method for droplet steeringUS7045537Sep 18, 2000May 16, 2006The University Of SussexProtein structures and protein fibresUS7491699Jun 9, 2005Feb 17, 2009Ramot At Tel Aviv University Ltd.Discrete tubular, spherical or planar nanostructure composed of aromatic homodipeptides; transistors, field emitters, display devices, memory chips, cooling systems, nano-mechanical devicesUS7504383Jun 9, 2005Mar 17, 2009Ramot At Tel Aviv University Ltd.metal at least partially enclosed by a discrete tubular, nanostructure composed of a plurality of aromatic homodipeptidesUS20010041732Mar 20, 2001Nov 15, 2001David GurleyUseUS20020006954Feb 27, 2001Jan 17, 2002Oklahoma Medical Research FoundationDesmethyl tocopherols for preventing or slowing degenerative neurological diseasesUS20020086067Dec 29, 2000Jul 4, 2002Choi Paula Y.Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidosesUS20020151506Mar 15, 2002Oct 17, 2002Castillo Gerardo M.Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disordersUS20030130484Mar 20, 2002Jul 10, 2003Gordon David J.A peptides for treating amyloid fibrils; drug screening for potential antagonist; antifibrillatory agentsUS20030144185May 10, 2002Jul 31, 2003Mcgimpsey William GrantNanotube structures formed from a plurality of stacked cyclic peptides comprising chromophore residues that provide molecular scale electronic conductivity and non linear optical behaviorUS20030158237Sep 4, 2002Aug 21, 2003Colba R & D Inc.Combination of antioxidant substances for the treatment of alzheimer's diseaseUS20030211007 *Jun 12, 2003Nov 13, 2003Lifestream Technologies, Inc.Diagnosis of heart diseaseUS20030225155Jun 4, 2002Dec 4, 2003Fernandez-Pol Jose A.Treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, heavy metal poisoning and immunogical diseases with thiophene-2-carboxylic acid, 2-furoic acid or derivativesUS20040029830Jul 31, 2003Feb 12, 2004Hebert Rolland F.Water-soluble indole-3-propionic acidUS20040052928Sep 6, 2002Mar 18, 2004Ehud GazitA peptide containing at least 5 amino acid residues and less than 15 amino acid residues;US20040152672Oct 9, 2003Aug 5, 2004Carson Dennis A.Indole compounds useful for the treatment of cancerUS20040258726 *Feb 11, 2004Dec 23, 2004Stupp Samuel I.Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereonUS20050069950Aug 29, 2003Mar 31, 2005Haynie Donald T.Method for designing polypeptides for the nanofabrication of thin films, coatings, and microcapsules by electrostatic layer-by-layer self assemblyUS20050124535 *Sep 29, 2004Jun 9, 2005Mcgimpsey William G.Cyclic peptide nanotube structures for molecular scale electronic and photonic devicesUS20060079454Jun 9, 2005Apr 13, 2006Ramot At Tel Aviv University Ltd.Discrete tubular, spherical or planar nanostructure composed of aromatic homodipeptides; transistors, field emitters, display devices, memory chips, cooling systems, nano-mechanical devicesUS20060079455Jun 9, 2005Apr 13, 2006Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing sameUS20060089380Jul 16, 2003Apr 27, 2006Prana Biotechnology Ltd.Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052)US20060089489 *Oct 19, 2005Apr 27, 2006Matsushita Electric Industrial Co., Ltd.Adding a conductor (optionally metal-plated gold particle) to a the smino groups of a nanofiber formed though self-assembly of a short peptide having a specific sequenceUS20060194777Mar 23, 2006Aug 31, 2006Ehud GazitCompositions and methods using same for treating amyloid-associated diseasesUS20060234947Jun 21, 2006Oct 19, 2006Tel Aviv University Future Technology Development L.PA synthetic dipeptide as set forth in SEQ ID NO: 145 - tryptophan-2-aminoisobutyric acid (D-Trp-Aib); diagnosing and treating Alzheimer's disease, non-insulin dependent diabtes; antdiabetic agents, prion-related encephalopathies such as bovine spongiform encephalo pathyUS20070015813May 30, 2006Jan 18, 2007Queen's University At KingstonTreatment of protein folding disordersUS20070021345Jun 29, 2004Jan 25, 2007Ehud GazitPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseasesUS20070099840Sep 7, 2006May 3, 2007The University Of ManchesterHydrogel compositionsUS20070135334Jan 23, 2007Jun 14, 2007Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosing and treating amyloid-associated diseasesUS20070298043Sep 27, 2004Dec 27, 2007Ehud GazitNovel Antibacterial Agents and Methods of Identifying and Utilizing SameUS20090061190Jun 5, 2005Mar 5, 2009Ramot At Tel Aviv University Ltd.Articles of peptide nanostructures and method of forming the sameUS20090123553Jan 2, 2009May 14, 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the sameUS20090175785Oct 15, 2006Jul 9, 2009Ehud GazitSelf-Assembled Fmoc-Ff HydrogelsUS20090263429Sep 7, 2006Oct 22, 2009The University Of ManchesterMethod of Preparing a HydrogelDE3412445A1Mar 31, 1984Oct 10, 1985Meyer Glauner Wilhelm DrCarrier tripeptide with antifungal activityDE10043282A1Sep 2, 2000Mar 28, 2002Kurt HeiningerMedicaments containing amyloid-beta-protein formation and/or secretion inhibitors, are used for treating hypertension, diabetes, arteriosclerosis, rheumatism, cardiac infarction, inflammation or sepsisEP0081122A1Nov 19, 1982Jun 15, 1983Helopharm W. Petrik GmbH &amp; Co.KG.Carrier tripeptides with antifungal activityEP0421946A2Sep 7, 1990Apr 10, 1991POLIFARMA S.p.A.3-indolepyruvic acid derivatives their method of production and therapeutic useEP0885904A1Jun 10, 1998Dec 23, 1998Fraunhofer-Gesellschaft Zur F�rderung Der Angewandten Forschung E.V.Peptides as agonists and/or inhibitors of amyloid formation and/or cytotoxicity and their use against Alzheimer's disease, type II diabetes mellitus and spongiform encephalopathyEP0966975A2Jun 4, 1999Dec 29, 1999Tokyo Gas Co., Ltd.Diagnostic agents for pancreatic exocrine functionRU2196568C1 Title not availableWO2000030683A1Nov 12, 1999Jun 2, 2000Tsunetoshi HonmaPreventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effectWO2004050693A1 *Dec 3, 2003Jun 17, 2004Gianfranco GilardiEngineering redox proteins* Cited by examinerNon-Patent CitationsReference1Ajayan et al. "Application of Carbon Nanotubes", Topics of Applied Physics, 80: 391-425, 2001.2Akazome et al. "Enantioselective Inclusion of Methyl Phenyl Sulfoxides and Benzyl Methyl Sulfoxides by (R)-Phenylglycyl-(R)-Phenylglycine and the Crystal Structures of the Inclusion Cavities", Journal of Organic Chemistry, 65(1): 68-76, 2000.3Altland et al. "Potential Treatment of Transthyretin-Type Amyloidoses by Sulfite", Neurogenetics, 2: 183-188, 1999.4Anguiano et al. "Protofibrillar Islet Amyloid Polypeptide Permeabilizes Synthetic Vesicles by A Pore-Like Mechnaism That May Be Relevant to Type II Diabetes", Biochemistry, 41: 11338-11343, 2002.5Appukkuttan et al. "Microwave Enhanced Formation of Electron Rich Arylboronates", Synlett, 8: 1204-1206, 2003. Figs. Scheme 4, Compounds 5A, 5B, 5C, 5D.6Arvinte et al. "The Structure and Mechanism of Formation of Human Calcitonin Fibrils", The Journal of Biological Chemistry, 268(9): 6415-6422, 1993.7Asghamejad "Ester Derivatives as Prodrugs", Transport Processes in Pharmaceutical Systems, 102: 186, 2000.8Austin et al. "Medical Progress: Calcitonin. Physiology and Pathophysiology", The New England Journal of Medicine, 304(5): 269-278, 1981.9Azriel et al. "Analysis of the Minimal Amyloid-Forming Fragment of the Islet Amyloid Polypeptide", The Journal of Biological Chemistry, 276(36): 34156-34161, 2001.10Balaram "De Novo Design: Backbone Conformational Constraints in Nucleating Helices and beta-Hairpins", Journal of Peptide Research, 54: 195-199, 1999.11Balaram "De Novo Design: Backbone Conformational Constraints in Nucleating Helices and β-Hairpins", Journal of Peptide Research, 54: 195-199, 1999.12Balbach et al. "Supramolecular Structure in Full-Length Alzheimer's beta-Amyloid Fibrils: Evidence for A Parallel beta-Sheet Organization From Solid-State Nuclear Magnetic Resonance", Biophysical Journal, 83: 1205-1216, 2002.13Balbach et al. "Supramolecular Structure in Full-Length Alzheimer's β-Amyloid Fibrils: Evidence for A Parallel β-Sheet Organization From Solid-State Nuclear Magnetic Resonance", Biophysical Journal, 83: 1205-1216, 2002.14Bauer et al. "Interfacial Adsorption and Aggregation Associated Changes in Secondary Structure of Human Calcitonin Monitored by ATR-FTIR Spectroscopy", Biochemistry, 33: 12276-12282, 1994.15Benvenga et al. "Homology of Calcitonin With the Amyloid-Related Proteins", Journal of Endocrinological Investigation, 17: 119-122, 1994.16Berger et al. "Calcitonin-Like Immunoreactivity of Amyloid Fibrils in Medullary Thyroid Carcinomas", Virchows Archiv A Pathological Anatomy and Histopathology, 412: 543-551, 1988.17Berson et al. "Proprotein Convertase Cleavage Liberates A Fibrillogenic Fragment of A Resident Glycoprotein to Initiate Melanosome Biogenesis", Journal of Cell Biology, 161(3): 521-533, 2003.18Beugelmans Database Crossfire Beilstein [Online], Beilstein Institut zur F?rderung der Chemischen Wissenschaften, Frankfurt am Main, DE, Database Accession No. 116671 (BRN) Compounds INDOL-2-YL-Methanol & Beugelmans R.: Bulletin de la Soci?t? Chimique Fran?aise, p. 335-336, 1969.19Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242(4877): 423-426, 1988.20Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.21Bong et al. "Self-Assembling Organic Nanotubes", Angewandte Chemie, International Edition,40:988-1011, 2001.22Changqing et al. "Amyloid-like Formation by Self-Assembly of Peptidolipids in Two Dimensions", Langmuir, 20: 8641-8645, 2004.23Chapman et al. "Role of Escherichia coli Curli Operons in Directing Amyloid Fiber Formation", Science, 295(5556): 851-855, 2002. Abstract.24Chapman et al. "Role of Escherichia coli Curti Operons in Directing Amyloid Fiber Formation", Science, 295(5556): 851-855, 2002, Abstract.25Cherny et al. "The YefM Antitoxin Defines A Family of Natively Unfolded Proteins", The Journal of Biological Chemistry, 279(9): 8252-8261, 2004.26Cherny et al. "The Formation of Escherichia coli Curli Amyloid Fibrils is Mediated by Prion-Like Peptide Repeats", Journal of Molecular Biology, 352(2): 245-252, 2005.27Choplin "Computers and the Medicinal Chemist", Comprehensive Medicinal Chemistry, 4(Chap.17.2): 33-58, 1990.28Chou et al. "Conformational Parameters for Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated From Proteins", Biochemistry, 13(2): 211-222, 1974.29Chou et al. "Empirical Predictions of Protein Conformation", Annual Reviews in Biochemistry, 47: 251-276, 1978.30Claessen et al. "A Novel Class of Secreted Hydrophodic Proteins is Involved in Aerial Hyphae Formation in Streptomyces Coelicolor by Forming Amyloid-Like Fibrils", Genes & Development, 17: 1714-1726, 2003.31Claessens et al. "Review Commentary: π-πInteractions in Self-Assembly", Journal of Physical Organic Chemistry, 10: 254-272, 1997.32Clark et al. "Self-Assembling Cyclic β3-Peptide Nanotubes as Artificial Transmembrane Ion Channels", Journal of the American Chemical Society, JACS, 120: 651-656, 1998.33Cohen et al "Inhibition of Amyloid Fibril Formation and Cytotoxicity by Hydroxyindole Derivatives", Biochemistry, 45: 4727-4735, 2006. Abstract, p. 4728, col. 1, Last �, p. 4728, co1. 2, � 2, Fig.1, p. 4729, co1. 1, p. 4728, col. 1 , Last �, p. 4728, col. 2, � 2, Fig.1, p. 4728, col. 1, Last �, p. 4728, co1. 2, � 2, Fig.1, 4, p. 4732, col. 2, � 2,3, p. 4733, col. 2, � 4.34Cole et al. "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer", Monoclonal Antibodies and Cancer Therapy, Proceedings of the Roche-UCLA Symposium, Park City, Utah, p. 77-96, 1985.35Communciation Pursuant to Article 96(2) EPC Dated Mar. 30, 2006 From the European Patent Office Re.: Application No. 04700494.0.36Communication Pursuant to Article 94(3) EPC Dated Aug. 11, 2009 From the European Patent Office Re.: Application No. 05747261.5.37Communication Pursuant to Article 94(3) EPC Dated Dec. 29, 2009 From the European Patent Office Re.: Application No. 03777149.0.38Communication Pursuant to Article 94(3) EPC Dated Jun. 8, 2010 From the European Patent Office Re.: Application No. 06796163.1.39Communication Pursuant to Article 94(3) EPC Dated Mar. 12, 2008 From the European Patent Office Re.: Application No. 05774727.1.40Communication Pursuant to Article 94(3) EPC Dated Sep. 15, 2009 From the European Patent Office Re.: Application No. 09002048.8.41Communication Pursuant to Article 94(3) EPC Dated Sep. 4, 2008 From the European Patent Office Re.: Application No. 03777149.0.42Communication Pursuant to Article 96(2) Dated Jul. 17, 2006 From the European Patent Office Re.: Application No. 03777149.0.43Communication Pursuant to Article 96(2) EPC Dated Jan. 14, 2007 From the European Patent Office Re.: Application No. 04700494.0.44Communication Pursuant to Article 96(2) EPC Dated May 14, 2007 From the European Patent Office Re.: Application No. 03777149.0.45Communication Pursuant to Rules 109 and 110 EPC Dated Aug. 18, 2005 From the European Patent Office Re.: Application No. 04700494.0.46Communication Under Rule 112 EPC Dated Mar. 31, 2006 From the European Patent Office Re.: Application No. 03777149.0.47Communication Under Rule 71(3) EPC Dated Oct. 7, 2008 From the European Patent Office Re.: Application No. 04700494.0.48Copp "Endocrine Regulation of Calcium Metabolism", Annual Reviews in Physiology, 32: 61-86, 1970.49Elliot et al. "The Chaplins: A Family of Hydrophobic Cell-Surface Proteins Involved in Aerial Mycelium Formation in Streptomyces Coelicolor", Genes & Development, 17: 1727-1740, 2003.50Engelberg-Kulka et al. "Bacterial Programmed Cell Death Systems as Targets for Antibiotics", Trends in Microbiology, 12(2): 66-71, 2004.51Examination Report Dated Jun. 19, 2006 From the Intellectual Property Office of India Re.: Application No. 1510/CHENP/2005.52Examination Report Dated May 10, 2007 From the Government of India, Patent Office Re.: Application No. 1499/CHENP/2005.53Examination Report Jan. 13, 2009 From the Government of India, Patent Office Re.: Application No. 1400/CHENP/2006.54Findeis et al. "Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization", Biochemistry, 38: 6791-6800, 1999.55Fingl et al. "Inroduction: General Principles", The Pharmacological Basis of Therapeutics, 5th Ed., Sec.I(Chap. 1): 1-53, 1975.56Fishwild et al. "High-Avidity Hum IgGκ Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.57Forloni et al. "Anti-Amyloidogenic Activity of Tetracyclines: Studies in Vitro", FEBS Letters, 487(3): 404-407, 2001. Figs. 1,3.58Ganesh et al. "Circular Dichroism and Fourier Transform Infrared Spectroscopic Studies on Self-Assembly of Tetrapeptide Derivative in Solution and Solvated Film", The Journal of Peptide Research: Official Journal of the American Peptide Society, 61(3): 122-128, Mar. 2003.59Gazit "A Possible Role for 'Phi'-Stacking in the Self-Assembly of Amyloid Fibrils", The FASEB Journal, 16: 77-83, 2002.60Gazit "Mechanisms of Amyloid Fibril Self-Assembly and Inhibition Model Short Peptides as A Key Research Tool", The FEBS Journal, 272: 5971-5978, 2005.61Gazit "A Possible Role for �Phi�-Stacking in the Self-Assembly of Amyloid Fibrils", The FASEB Journal, 16: 77-83, 2002.62Gazit "Mechanistic Studies of Process of Amyolid Fibrils Formation by the Use of Peptide Fragments and Analogues: Implications for the Design of Fibrillization Inhibitors", Current Medicinal Chemistry, 9: 1725-1735, 2002.63Ghardiri et al. "Artificial Transmembrane Ion Channels from Self-Assembling Peptide Nanotubes", Nature,369(6478):301-304, 1994.64Gillard et al. "Controlling Self-Assembly", Chemical European Journal, 3(12): 1933-1940, 1997.65Goerbitz "Nanotube Formation by Hydrophobic Dipeptides", Chemical European Journal, 7(23): 5153-5159, 2001.66G�rbitz "Nanotube Formation by Hydrophobic Dipeptides", Chemistry, 7(23): 5153-5159, 2001, Abstract.67Grady et al. "Axe-Txe, A Broad-Spectrum Proteic Toxin-Antitoxin System Specified by a Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium", Molecular Microbiology, vol. 47(5: p. 1419-1432, 2003.68Grady et al. "Axe-Txe, A Broad-Spectrum Proteic Toxin-Antitoxin System Specified by A Multidrug-Resistant, Clinical Isolate of Enterococcus Faeciurn", Molecular Biology, 47(5): 1419-1432, 2003. Abstract, p. 1424, col. 1-p. 1426, col. 2, Fig.5.69Grady et al. "Axe-Txe, A Broad-Spectrum Proteic Toxin�Antitoxin System Specified by a Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium", Molecular Microbiology, vol. 47(5: p. 1419-1432, 2003.70Grateau "[Coli's Curli or How Amyloid Can be Physiological.]", M�decine Sciences, 18(6-7): p. 664, 2002.71H�ggqvist et al. "Medin: An Integral Fragment of Aortic Smooth Muscle Cell-Produced Lactadherin Forms the Most Common Human Amyloid", Proc. Natl. Acad. Sci. USA, 96: 8669-8674, 1999.72Haldar et al. "First Crystallographic Signature of the Highly Ordered Supramolecular Helical Assemblage from a Tripeptide Containing a Non-Coded Amino Acid", Tetrahedron Letters, 43(14): 2653-2656, 2002, Abstract.73Harlow et al. "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory, p. III-IX, 1988.74Harrison et al. "Amyloid Peptides and Proteins in Review", Reviews in Physiology, Biochemistry and Pharmacology, 159: 1-77, 2007.75Hartgerink et al. "Peptide Nanotubes and Beyond", Chemistry European Journal, 4(8): 1367-1372, 1998, Abstract.76Hayden et al. "�A� Is for Amylin and Amyloid in Type 2 Diabetes Mellitus", JOP Journal of the Pancreas (Online), 2(4): 124-139, 2001.77Higaki et al. "Regulation of Drug Absorption From Small Intestine by Enteric Nervous System 1: A Poorly Absorbable Drug Via Passive Diffusion", Drug Metabolism and Pharmacokinetics, 19(3): 198-205, 2004.78Holmes et al. "Extensive Neurite Outgrowth and Active Synapse Formation on Self-Assembling Peptide Scaffolds", Proc. Natl. Acad. Sci. USA, 97(12): 6728-6733, 2000.79Honma et al. "Use of A Thromboxane A2 Antagonist or Synthase Inhibitor for Treating Central Nervous System Diseases, e.g. Alzheimer Type Dementia." Database WPI, Section Ch. Week 200039, Derwent Publications, AN 2000-451668. & WO 00/30683 (Yagami et al.), Jun. 2, 2000. Abstract.80Hoogenboom et al. "By-Passing Immunisation. Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227: 381-388, 1992.81Hoyle et al. "Pseudomonas Aeruginosa Biofilm as A Diffusion Barrier to Piperacillin", Antimicrobial Agents and Chemotherapy, 36(9): 2054-2056, 1992.82Huang et al. "A Review on Polymer Nanofibers by Electrospinning and Their Applications in Nanocomposites", Composites Science and Technology, 63: 2223-2253, 2003.83Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.84Inglot "Comparison of the Antiviral Activity In Vitro of Some Non-Steroidal Anti-Inflammatory Drugs", Journal of General Virology, 4(2): 203-214, 1969.85International Preliminary Report of Patentability Dated Mar. 17, 2006 From the International Preliminary Examining Authority Re.: Application No. PCT/IL2004/000890.86International Preliminary Report on Patentability Dated Apr. 13, 2006 From the International Bureau of WIPO Re.: Application No. PCT/IL2004/000898.87International Preliminary Report on Patentability Dated Apr. 24, 2008 From the International Bureau of WIPO Re.: Application No. PCT/IL2006/001174.88International Preliminary Report on Patentability Dated Feb. 15, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000589.89International Preliminary Report on Patentability Dated Jan. 22, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2004/000577.90International Preliminary Report on Patentability Dated Jan. 25, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000754.91International Preliminary Report on Patentability Dated Mar. 1, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000902.92International Preliminary Report on Patentability Jan. 22, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000954.93International Search Report and the Written Opinion Dated Aug. 22, 2007 From the International Searching Authority Re.: Applicaiton No. PCT/IL2006/001174.94International Search Report and the Written Opinion Dated Jul. 15, 2008 From the International Searching Authority Re.: Application No. PCT/IL05/00954.95International Search Report Dated Aug. 16, 2005 From the International Searching Authority Re.: Application No. PCT/IL2004/000898.96International Search Report Dated Jul. 19, 2004 From the International Searching Authority Re.: Application No. PCT/IL03/01045.97International Search Report Dated May 10, 2004 From International Searching Authority Re.: Application No. PCT/IL2004/000012.98Jack et al. "The Organization of Aromatic Side Groups in an Amyloid Fibril Probed by Solid-State 2H and 19F NMR Spectroscopy", Journal of the American Chemical Society, JACS, 128: 8098-8099, 2006.99Jayawarna et al. "Nanostructured Hydrogels for Three-Dimensional Cell Culture Through Self-Assembly of Fluorenylmethoxycarbonyl-Dipeptides", Advanced Materials, 18: 611-614, 2006.100Jin "Electrospinning Bombyx Mori Silk With Poly (Ethylene Oxide)" Biomacromolecules, 3: 1233-1239, 2002.101Jones et al. "Replacing the Complementarity-Determining Regions in A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.102Kamihira et al. "Conformational Transitions and Fibrillation Mechanism of Human Calcitonin as Studied by High-Resolution Solid-State 13C NMR [in Process Citation]", Protein Science, 9: 867-877, 2000.103Kanaori et al. "Study of human Calcitonin Fibrillation by Proton Nuclear Magnetic Resonance Spectroscopy", Biochemistry, 34: 12138-12143, 1995.104Kaplan "Fibrous Proteins-Silk as a Model System", Polymer Degradation and Stability, 59: 25-32, 1998.105Kapurniotu et al. "Structure-Based Design and Study of Non-Amyloidogenic, Double N-Methylated IAPP Amyloid Core Sequences as Inhibitors of IAPP Amyloid Formation and Cytotoxicity", Journal of Molecular Biology, 315: 339-350, 2002.106Kedar et al. "In Vitro Synthesis of �Amyloid� Fibrils From Insulin, Calcitonin and Parathormone", Israel Journal of Medical Science, 12(10): 1137-1140, 1976.107 *Kerman et al., "Peptide Nucleic Acid-Modified Carbon Nanotube Field-Effect Transistor for Ultra-sensitive Real-Time Detection of DNA Hybridization," NanoBiotechnology, vol. 1, No. 1, Mar. 2005.108Kimura et al. "Analysis and Prediction of Absorption Profile Including Hepatic First-Pass Metabolism of N-Methyltyramine, A Potent Stimulant of Gastrin Release Present in Beer, After Oral Ingestion in Rats by Gastrointestinal-Transit-Absorption Model", Drug Metabolism and Disposition, 28(5): 577-581, 2000.109Kiselev "Pharmaceutical Composition for Prophylaxis and Treatment of Uterus Cervix Dysplasia and Cancer and Larynx Papillomatosis and Methods of Prophylaxis and Treatment of Said Sicknesses Based on Thereof", Database WPI, Section Ch, Week 200328, Derwent Publications, AN 2003-286683 & RU 2196568 C1 (Kiselev) Jan. 20, 2003. Abstract.110Kisilevsky et al. "Arresting Amyloidosis In Vivo Using Small-Molecule Anionic Sulphonates or Sulphates: Implications for Alzheimer's Disease", Nature Medicine, 1: 143-148, 1995. Abstract.111Kocisko et al. "New Inhibitors of Scrabie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products", Journal of Virology, 77(19): 10288-10294, 2003.112Kon-Ya et at "Indole Derivatives as Potent Inhibitors of Larval Settlement by the Barnacle, Balanus Amphitrite", Bioscience Biotechnology Biochemistry, JP, 58(12): 2178-2181, 1994. Compound 102.113Kubik "High-Performance Fibers from Spider Silk", Angewandte Chemie, International Edition, 41(15): 2721-2723, 2002.114Kyte et al. "A Simple Method for Displaying the Hydropathic Character of A Protein", Journal of Molecular Biology, 157: 105-132, 1982.115Lansbury "Following Nature's Anti-Amyloid Strategy", Nature Biotechnology, 19(2): 112-113, 2001. p. 112, Left-Hand Col., Paragraph 1-Middle Col., Paragraph 1.116Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to Methods in Enzymology, 2(2): 106-110, 1991.117Lashuel et al. "New Class of Inhibitors of Amyloid-? Fibril Formation Implications for the Mechanism of Pathogenesis in Alzheimer's Disease", The Journal of Biological Chemistry, 277(45): 42881-42890, 2002.118Lazaris et al. "Spider Silk Fibers Spun From Soluble Recombinant Silk Produced in Mammalian Cells", Science, 295: 472-476, 2002. p. 474-475.119Lee et al. "Anti-Diabetic Constituent From the Node of Lotus Rhizome (Nelumbo Nucifera Gaertn)", Natural Product Sciences, 7(4), 107-109, 2001. p. 108, col. 1; Last �-col. 2, � 1.120Li et al. "Amyloid-Like Formation by Self-Assembly of Peptidolipids in Two Dimensions", Langmuir: The ACS Journal of Surfaces and Colloids, XP002529300, 20(20): 8641-8645, Aug. 25-Sep. 28, 2004.121Liao et al. "Triphenylmethane Dyes as Inhibitors of Reverse Transcriptase RNA Polymerase and Protein Synthesis: Structure Activity Relationships", Journal of Medicinal Chemistry, 18(1): 117-120, 1975. Abstract.122Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368(6474): 856-859, 1994.123Lonberg et al. "Human Antibodies From Transgenic Mice", International Review of Immunology, 13: 65-93, 1995.124Losert et al. "Effect of Indole 3 Alkanecarboxylic Acifs on Glucose Utilization in Rats" Arzneimittel-Forschung/Drug Research, 25(6): 880-887, 1975. p. 880, col. 1, � 6, p. 886, col. 2, � 4, 5, p .887, col. 1, � 3.125Lowe et al. "Structure-Function Relationships for Inhibitors of β-Amyloid Toxicity Containing the Recognition Sequence KLVFF", Biochemistry, 40: 7882-7889, 2001.126Lyon et al. "Self-Assembly and Gelation of Oxidized Gluthathione in Organic Solvents", Journal of the American Chemical Society, 123: 4408-4413, 2001.127MacPhee et al. "Engineered and Designed Peptide-Based Fibrous Biomaterials", Current Opinion in Solid State and Materials Science, XP002529298, 8(2): 141-149, Mar. 2004.128Mah et al. "A Genetic Basis for Pseudomonas Aeruginosa Biofilm Antibiotic Resistance", Nature, 426: 306-310, 2003.129Mahler et al. "Rigid, Self-Assembled Hydrogel Composed of A Modified Aromatic Dipeptide", Advanced Materials, 18(11): 1365-1370, 2006.130Maji et al. "Fibril-Forming Model Synthetic Peptides Containing 3-Aminophenylacetic Acid", Tetrahedron, 58(43): 8695-8702, 2002, Abstract.131Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, 10: 779-783, 1992.132Marks et al. "By-Passing Immunization�Human Antibodies from V-Gene Libraries Displayed on Phage", Journal of Molecular Biology, 222: 581-597, 1991.133Martin et al. "The Emerging Field of Nanotube Biotechnology", Nature Reviews: Drug Discovery, 2(1): 29-37, Jan. 2003. Abstract.134Maury et al. "Creation of Amyloid Fibrils From Mutant ASN187 Gelsolin Peptides", Biochemical and Biophysical Research Communications, 183(1): 227-231, 1992.135McGaughey et al. "n-Stacking Interactions", The Journal of Biological Chemistry, 273(25): 15458-15463, 1998.136McPhee et al. "Engineered and Designed Peptide-Based Fibrous Biomaterials", Current Opinion in Solid State and Materials Science, 8(2): 141-149, Mar. 2004.137Meluleni et al. "Mucoid Pseudomonas Aeruginosa Growing in A Biofilm in Vitro are Killed by Opsonic Antibodies to the mucoid Exopolysaccharide Capsule but Not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients1 ,2", Journal of Immunology , 155:2029-2038, 1995.138Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994.139Mosmann "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays", Journal of Immunological Methods, 65: 55-63, 1983.140Mosselman et al. "The Complete Islet Amyloid Polypeptide Precursor Is Encoded by Two Exons", FEBS Letters, 247: 154-158, 1989, Database Accession No. S04016.141Murphy et al. "Biofilm Formation by Nontypeable Haemophilus Influenzae: Strain variability, Outer Membrane Antigen Expression and Role of pili", BMC Microbiology, 2(7): 1471-2180, 2002.142Mutter "Studies on the Coupling Rates in Liquid-Phase Peptide Synthesis Using Competition Experiments", International Journal of Peptide Protein Research, 13: 274-277, 1979.143Nakajima "Amine Precursor Therapy: Manipulation of Brain Amine Activity With Precursor Amino Acid", Psychiatry and Clinical Neurosciences, 51(5), 267-274, 1997. p. 269, col. 1, � 2, 3.144Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 14: 826, 1996.145Nicolaus "Symbiotic Approach to Drug Design", Decision Making in Drug Research, p. 173-186, 1983.146Notice of Allowability Dated May 21, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/662,136.147Notice of Allowance Dated Jun. 18, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.148Notice of Allowance Dated Mar. 26, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/662,136.149Notice of Allowance Dated Sep. 16, 2008 From the US Patent Office Re.: U.S. Appl. No. 11/148,262.150Notice of Allowance Dated Sep. 17, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,266.151OA Feb. 1, 2009 W Sec 8, Israeli Office action.152OA of Jan. 8, 2009 W Sec 8, Israeli Office action.153Offen et al. "A Low Molecular Weight Copper Chelator Crosses the Blood-Brain Barrier and Attenuates Experimental Autoimmune Encephalomyelitis", Journal of Neurochemistry, 89: 1241-1251, 2004.154Offical Action Dated Feb. 23, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/235,852.155Office Action Dated Aug. 4, 2009 From the Israel Patent Office Re.: Application No. 169120 and Its Translation Into English.156Office Action Dated Aug. 4, 2009 From the Israeli Patent Office Re.: Application No. 169120 and Its Translation Into English.157Office Action Dated Jul. 14, 2009 From the Israel Patent Office Re.: Application No. 169121 and Its Translation Into English.158Office Action Dated Jun. 17, 2010 From the Israel Patent Office Re.: Application No. 169120 and Its Translation Into English.159Office Action Dated Mar. 28, 2007 From the Israel Patent Office Re.: Application No. 169120.160Office Action Dated May 30, 2010 From the Israel Patent Office Re.: Application No. 169121 and Its Translation Into English.161Office Action Dated Sep. 15, 2008 From the Israeli Patent Office Re.: Application No. 169121 and Its Translation Into English.162Office Action Dated Sep. 15, 2008 From the Israeli Patent Office Re.: Appliction No. 169120 and Its Translation Into English.163Official Action Dated Apr. 10, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/386,880.164Official Action Dated Apr. 19, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/901,243.165Official Action Dated Apr. 3, 2009 From the US Patent Trademark Office Re.: U.S. Appl. No. 11/662,136.166Official Action Dated Apr. 30, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.167Official Action Dated Aug. 30, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/318,619.168Official Action Dated Dec. 11, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/318,653.169Official Action Dated Dec. 12, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/656,542.170Official Action Dated Dec. 16, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/562,852.171Official Action Dated Dec. 3, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/574,405.172Official Action Dated Feb. 15, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.173Official Action Dated Jul. 22, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/318,653.174Official Action Dated Jun. 22, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/318,653.175Official Action Dated Jun. 30, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/662,136.176Official Action Dated Jun. 9, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/662,136.177Official Action Dated May 2, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/656,542.178Official Action Dated Sep. 19, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.179Official Action Dated Sep. 27, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,266.180Oza et al. "Synthesis and Evaluation of Anthranilic Acid-Based Transthyretin Amyloid Fibril Inhibitors", Bioorganic & Medicinal Chemistry Letters, 9: 1-6, 1999.181Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole Anitbodies, Produced by High Cell Density Fermentation of Escherichia coli", Bio/Technology, 11: 1271-1277, 1993.182Partial European Search Report and the European Search Opinion Dared Apr. 16, 2009 From the European Patent Office Re.: Application No. 09002048.8.183Patani et al. "Bioisosterism: A Rational Approach in Drug Design", Chemical Reviews, 96(8): 3147-3176, 1996.184Pavia et al. "Antimicrobial Activity of Nicotine Against a Spectrum of Bacterial and Fungal Pathogens", Journal of Medical Microbiology, 49(7): 675-676, 2000.185Peterson et al. "Inhibiting Transthyretin Conformational Chamges That Lead to Amyloid Fibril Formation", Proc. Natl. Acad. Sci. USA, 95: 12956-12960, 1998.186Petkova et al. "A Structural Model for Alzheimer's β-Amyloid Fibrils Based on Experimental Constraints From Solid State NMR", Proc. Natl. Acad. Sci. USA, 99(26): 16742-16747, 2002.187Pettmann et al. "Morphological and Biochemical Maturation of Neurones Cultured in the Absence of Glial Cells", Nature, 281: 378-380, 1979.188Pispisa et al. "A Spectroscopic and Molecular Mechanics Investigation on A Series of AIB-Based Linear Peptides and A Peptide Template, Both Containing Tryptophan and A Nitroxide Derivative as Probes", Biopolymers, 53: 169-181, 2000.189Porter "The Hydrolysis of Rabbit γ-Globulin and Antibodies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.190Presta "Antibody Engineering", Current Opinion in Structural Biology, 2: 593-596, 1992.191Puchtler et al. "A Review of Early Concepts of Amyloid in Context With Contemporary Chemical Literature From 1839 to 1859", The Journal of Histochemistry and Cytochemistry, 14(2): 123-134, 1966.192Rajagopal et al. "Self-Assembling Peptides and Proteins for Nanotechnological Applications", Current Opinion in Structural Biology, 002529297, 14(4): 480-486, Aug. 2004.193Reches et al. "Designed Aromatic Homo-Dipeptides: Formation of Ordered Nanostructures and Potential Nanotechnological Applications", Physical Biology, 3: S10-S19, 2006.194Reches et al. "Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin", The Journal of Biological Chemistry, 277(38): 35475-35480, 2002.195Reches et al. "Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes", Science, 300(5619): 625-627, 2003, Abstract.196Reches et al. "Self-Assembly of Peptide Nanotubes and Amyloid-Like Structures by Charged-Termini-Capped Diphenylalanine Peptide Analogues", Israel Journal of Chemistry, XP009087914, 45(3): 363-371, Jun. 30, 2005.197Reches et al. "Self-Assembly of Peptide Nanotubes and Amylois-Like Structures by Charged-Termini-Capped Diphenylalanine Peptide Analogues", Israel Journal of Chemistry, 45(3): 363-371, 2005.198Reches et al. "Supporting Online Material", Science, 300(5619): 1-9, 2003. Retrieved From the Internet: URL:http://www.sciencemag.org/cgi/data/300/5619/625/DC1.199Response Dated Apr. 12, 2010 to Official Action of Dec. 11, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/318,653.200Response Dated Apr. 22, 2010 to Communication Pursuant to Article 94(3) EPC of Dec. 29, 2009 From the European Patent Office Re.: Application No. 03777149.0.201Response Dated Dec. 13, 2007 to Communication Pursuant to Article 96(2) EPC of Jul. 17, 2006 From the European Patent Office Re.: Application No. 03777149.0.202Response Dated Dec. 9, 2009 to Communication Pursuant to Article 94(3) EPC of Aug. 11, 2009 From the European Patent Office Re.: Application No. 05747261.5.203Response Dated Jan. 12, 2010 to Communication Pursuant to Article 94(3) EPC of Sep. 15, 2009 From the European Patent Office Re.: Application No. 09002048.8.204Response Dated Jul. 9, 2008 to Notice of Allowance of Jun. 18, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.205Response Dated Mar. 9, 2009 to Communication Pursuant to Article 94(3) EPC of Sep. 4, 2008 From the European Patent Office Re.: Application No. 03777149.0.206Response Dated May 22, 2007 to Communication Pursuant to Article 96(2) EPC of Jan. 18, 2007 From the European Patent Office Re.: Application No. 04700494.0.207Response Dated May 25, 2007 to Communication Pursuant to Article 94(3) of Jan. 18, 2007 From the European Patent Office Re.: Application No. 04700494.0.208Response Dated Nov. 15, 2009 to Office Action of Jul. 14, 2009 From the Israeli Patent Office Re.: Application No. 169121.209Reza et al "Self-assembling Organic Nanotubes Based on a Cyclic Peptide Architecture", Nature 366:324-327 (1993).210Riechmann et al. "Reshaping Human Antibodies for Therapy", Nature, 332: 323-329, 1988.211Ryadnov et al. "Engineering the Morphology of a Self-Assembling Protein Fibre", Nature Materials, XP002529299, 2(5): 329-332, May 2003.212Ryadnow et al. "Engineering the Morphology of a Self-Assembling Protein Fibre", Nature Materials, 2(5): 329-332, May 2003.213Sacchettini et al. "Therapeutic Strategies for Human Amyloid Diseases", Nature Reviews: Drug Discovery, 1: 267-275, 2002.214Sano "Prevention of Alzheimer's Disease: Where We Stand", Current Neurology and Neuroscience Reports, 2(5): 392-399, Oct. 2002. Abstract.215Second Notice of Allowance Dated Sep. 16, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/148,262.216Shetty et al. "Aromatic π-Stacking in Solution as Revealed Through the Aggregation of Phenylacetylene Macrocycles", Journal of the American Chemical Society, 118: 1019-1027, 1996.217Sigel-Causey et al. "Phylogeny of the Pelecaniformes: Molecular Systematics of A Privative Group", Avian Molecular Evolution and Systematics, academic Press, p. 159-171, NBCI GenBank, Accession No. AAB58518, 1997.218Solomon et al. "Disaggregation of Alzheimer β-Amyloid by Site-Directed MAb", Proc. Natl. Acad. Sci. USA, 94: 4109-4112, 1997.219Soto et al. Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in A Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy, Nature Medicine, 4(7): 822-826, 1998.220Stephenson et al. "The �Promiscuous Drug Concept� With Applications to Alzheimer's Disease", FEBS Letters, 579: 1338-1342, 2005.221Stewart "Theoretical Aspects of Antibiotic Diffusion Into Microbial Biofilms", Antimicrobial Agents and Chemotherapy, 40(11): 2517-2522, 1996.222Sun et al. "Aromatic Van der Waals Clusters: Structure and Nonrigidity", Journal of Physical Chemistry, 100: 13348-13366, 1996.223Supplementary European Search Report Dated Apr. 18, 2006 From the European Patent Office Re.: Application No. 03704977.2.224Supplementary European Search Report Dated Jun. 10, 2009 From the European Patent Office Re.: Application No. 05747261.5.225Supplementary European Search Report Dated May 26, 2009 From the European Patent Office Re.: Application No. 05747261.226Tjernberg et al. "Arrest of β-Amyloid Fibril Formation by A Pentapeptide Ligand", The Journal of Biological Chemistry, 271(15): 8545-8548, 1996.227Tjernberg et al. "Controlling Amyloid β-Peptide Fibril Formation With Protease-Stable Ligands", The Journal of Biological Chemistry, 272(19): 12601-12605, 1997.228Toledano et al. "Enzyme-Triggered Self-Assembly of Peptide Hydrogels Via Reversed Hydrolysis", Journal of the American Chemical Society, JACS, 128(4): 1070-1071, 2006.229Tonkinson et al. "Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents", Cancer Investigation, 14(1): 54-65, 1996.230True et al. "Epigenetic Regulation of Trenslation Reveals Hidden Genetic Variation to Produce Complex Traits", Nature, 431: 184-187, 2004.231Tsai et al. "Synthesis of AIB-Containing Peptidomimetics as Potential Inhibitors of Alzheimer's γ-Secretase", 218th ACS National Meeting, New Orleans, USA, Meeting Abstract, MEDI-018, 1999. Abstract.232Tsang et al. "A Simple Chemical Method of Opening and Filling Carbon Nanotubes", Nature, 372: 159-162, 1994.233Tuite et al. "Propagation of Yeast Prions", Nature Reviews, 4: 878-889, 2003.234Vauthey et al. "Molecular Self-assembly of Surfactant-Like Peptides to form Nanotubes and Nanovesicles", PNAS,99(8):5355-5360, 2002.235Verhoeyen et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239: 1534-1536, 1988.236Vidal et al. "A Stop-Codon Mutation int he BRI Gene Associated With Familial British Dementia", Nature, 399: 776-781, 1999.237Westwater et al. "Use of Genetically Engineered Phage to Deliver Antimicrobial Agents to Bacteria: An Alternative Therapy for Treatment of Bacterial Infections", Antimicrobial Agents and Chemotherapy, 47 (4): 1301-1307, 2003.238Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A Companion to Methods in Enzymology, 2(2): 97-105, 1991.239Wolfenden et al. "Affinities of Amino Acid Side Chains for Solvent Water", Biochemistry, 20: 849-855, 1981.240Written Opinion Not Dated From the International Searching Authority Re.: Application No. PCT/IL2004/000898.241Yokoi et al. "Dynamic Reassembly of Peptide RADA16 Nanofiber Scaffold", Proc. Natl. Acad. Sci. USA, 102(24): 8414-8419, 2005.242Zaidi et al. "Forty Years of Calcitonin�Where Are We Now? A Tribute to the Work of lain Macintyre, FRS", Bone, 30(5): 655-663, 2002.243Zhang "Fabrication of Novel Biomaterials Through Molecular Self-Assembly", Nature Biotechnology, 21(10): 1171-1178, Oct. 1, 2003.244Zhang et al. "Design of Nanostructured Biological Materials Through Self-Assembly of Peptides and Proteins", Current Opinion in Chemical Biology, 6: 865-871, 2002.245Zhang et al. "Supramolecular Hydrogels Respond to Ligand-Receptor Interaction", Journal of the American Chemical Society, 125(45): 13680-13681, 2003.246Zhao et al. "Fabrication of Molecular Materials Using Peptide Construction Motifs", Trends in Biotechnology, 22(9): 470-476, Sep. 1, 2004.* Cited by examinerClassifications U.S. Classification204/403.01International ClassificationG01N27/327Cooperative ClassificationC25B11/0447European ClassificationC25B11/04D2Legal EventsDateCodeEventDescriptionDec 13, 2006ASAssignmentOwner name: RAMOT AT TEL AVIV UNIVERSITY LTD., ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEMINI, MIRI;RECHES, MEITAL;RISHPON, JUDITH;AND OTHERS;REEL/FRAME:018622/0408;SIGNING DATES FROM 20051116 TO 20061121Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEMINI, MIRI;RECHES, MEITAL;RISHPON, JUDITH;AND OTHERS;SIGNING DATES FROM 20051116 TO 20061121;REEL/FRAME:018622/0408Nov 30, 2006ASAssignmentOwner name: RAMOT AT TEL AVIV UNIVERSITY LTD., ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEMINI, MIRI;RECHES, MEITAL;RISHPON, JUDITH;AND OTHERS;REEL/FRAME:018565/0206;SIGNING DATES FROM 20061115 TO 20061121Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEMINI, MIRI;RECHES, MEITAL;RISHPON, JUDITH;AND OTHERS;SIGNING DATES FROM 20061115 TO 20061121;REEL/FRAME:018565/0206RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google